Cerebral Sporotrichosis in a Transplant Recipient: A Case Report (ATC 2026) - Jun 17, 2026 - Abstract #Abstract C297; Pres time: Jun 22, 2026; 02:45 PM - 03:45 PM; Location: Exhibit Hall; "Itraconazole is the first-line therapy for cutaneous sporotrichosis, but the optimal drug for central nervous system (CNS) infection remains unknown.* We present a case of CNS sporotrichosis in a transplant recipient and the literature review.* A 51-year-old female underwent simultaneous liver and kidney transplantation in 2019 and was maintained on immunosuppression with tacrolimus, mycophenolate mofetil, and prednisone...By day 37, despite stable serial brain imaging and no additional molds identified in CSF samples, the patient's mental status deteriorated, leading to the initiation of high-dose dexamethasone for its anti-inflammatory effects. On hospital day 39, antifungal susceptibility testing of the isolate revealed the following minimum inhibitory concentrations: amphotericin B 4, itraconazole 0.5, posaconazole 1, voriconazole >16, and isavuconazole >16 μg/mL... Around 50 cases of CNS sporotrichosis have been reported in the literature,..."
Case report • Clinical • Cardiovascular • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Pneumonia • Respiratory Diseases • Transplantation • Ventriculomegaly
|
|
I. Hunter 1; M. E. Salam 2; M. Casias 2; B. McCollister 1; C. Chiu 1
|